Health-Related Quality of Life (HRQOL) is an important outcome measure in the study of prostate cancer. There are few data regarding the effect of sociodemographic variables, such as insurance status, educational level, marital status or income, on HRQOL. We examined whether these or other sociodemographic and clinical variables are predictive of HRQOL outcomes using an observational database of prostate cancer patients accrued from a wide array of clinical practice settings.
Introduction
Clinical prostate cancer research has traditionally focused on outcomes such as local recurrence, evidence of metastases and disease-free and overall survival rates. In the past ®ve years, however, there has been a movement towards more re®ned endpoints that account for patients' subjective experience of their disease. In particular, health-related quality of life (HRQOL) has become such an important measure in clinical prostate cancer research that some authors now feel that`a modern trial of prostate cancer treatment should be regarded as insuf®-cient without including a validated Quality of Life Questionnaire. ' 1 To this end, new instruments have been developed that measure both general and disease-speci®c HRQOL in prostate cancer patients. 2, 3 While several studies have examined the effect of various treatment choices on quality of life outcomes, 2,3,8±16 there is little published information regarding factors prognostic of HRQOL in men with prostate cancer. While some researchers have examined the relationship of marital status and mortality in prostate cancer, 17±18 none has addressed the effect of marital status on HRQOL outcomes. Furthermore, few studies have speci®cally addressed the effect of age 19 or insurance status on quality of life outcomes in prostate cancer. This study was designed to examine whether these and other sociodemographic and clinical variables are predictive of HRQOL outcomes in prostate cancer patients. To answer these questions we utilized data from CaPSURE TM (Cancer of the Prostate Strategic Urologic Research Endeavor), a large national database of prostate cancer patients followed in a naturalistic setting. 4 Observational databases of this type have been used successfully in the past for the study of a number of other chronic illnesses, including AIDS, 5 rheumatoid arthritis, 6 and coronary artery disease. 7 CaPSURE TM is the ®rst database of its type to study the relationship of clinical and HRQOL information in a cohort of prostate cancer patients.
Materials and methods
The CaPSURE TM database CaPSURE TM was initiated in 1995 as an observational database to track men with prostate cancer in a variety of clinical practice settings. Patients are enrolled at 29 clinical sites located throughout the United States representing a variety of community and academic settings. The project accrues newly and previously diagnosed patients at all stages without regard to treatment selection. CaPSURE TM incorporates many important methodological elements of other successful chronic disease databases while evaluating a variety of health outcomes (clinical, HRQOL, and economic) associated with prostate cancer and its treatment. Enrollment is offered to patients with biopsy-proven prostate cancer regardless of disease duration, treatment choice, or severity of illness. At the time of enrollment, patients complete an extensive questionnaire on baseline demographics, comorbidities and HRQOL. Subsequently, at 3-month intervals, patients are mailed follow-up questionnaires to reassess HRQOL, comorbidities, and economic impacts of prostate cancer and its treatments. Telephone calls are conducted when information is incomplete or unclear. All data and research records are maintained in a con®dential database at Technology Assessment Group (San Francisco, CA). To assure standardization in data collection across the wide range of practice settings that contribute to CaPSURE TM , a research advisory panel composed of urologists, internists and outcomes researchers oversees the entire project. A detailed description of the rigorous quality control mechanisms and database maintenance techniques in CaPSURE TM is reported elsewhere. 4 
Subjects
For the current study, we identi®ed all patients who were enrolled in CaPSURE TM from June, 1995 through November, 1995 with a new diagnosis of prostate cancer, regardless of stage. A minimum of nine months of clinical and HRQOL follow-up data following diagnosis was required for inclusion in our study. Of the 2072 patients enrolled in CaPSURE TM as of June 1997, we identi®ed 131 newly diagnosed patients who had at least nine months of follow-up data. The remaining patients were excluded because they either had fewer than nine months followup or had been initially diagnosed more than six months prior to enrollment.
Instruments and data collection
At the time of enrollment into CaPSURE TM , patients completed a survey that assessed baseline social and demographic variables (such as age, ethnicity, marital and relationship status, employment status, education, annual household income) and a comorbidity count. Patients also completed a quality of life survey that assessed both general and disease-speci®c HRQOL. General HRQOL was measured using the RAND 36-Item Health Survey 1.0, better known as the SF-36. The SF-36 has been extensively validated in a variety of patient populations and is generally considered to be the`gold standard' for assessing general HRQOL. The SF-36 measures general HRQOL in eight domains, four physical and four emotional, each of which is scored from 0±100, with higher scores representing better quality of life.
20±21 Several additional scales used to measure general HRQOL included the Health Distress Scale from the RAND Medical Outcomes Study (MOS) 22 and a scale measuring patient self esteem, developed and validated by Technology Assessment Group. 23 Disease-speci®c HRQOL was measured with the UCLA Prostate Cancer Index, a 20-item instrument that encompasses urinary, bowel, and sexual disturbances. Its six domains have been previously validated in men with prostate cancer, and have been used in multiple HRQOL outcomes studies throughout the United States. 3 Two additional scales, developed and validated by Technology Assessment Group, 23 were used to assess the extent to which prostate cancer interfered with the patient's relationship with his family (Cancer Interference with Family) or with the patient's life in general (Cancer Interference). Each of the disease-speci®c scales is scored on a 0±100 range, similar to the SF-36, with higher scores representing better outcomes. Patients completed the same quality of life survey three, six, and nine months after baseline. Clinical data, such as tumor stage, are entered by the enrolling urologist at the time of initial visit and revised as necessary during subsequent visits. For the current study, data were analyzed from the baseline clinical, sociodemographic, and HRQOL surveys and from the 9-month HRQOL survey.
Statistical analysis
Descriptive statistics are reported for baseline scores in each HRQOL scale. A change score for each scale was calculated by subtracting the baseline HRQOL score from the 9-month HRQOL score. Mean scores at baseline and nine months were contrasted by comparing the change score to zero using the paired Student t-test. Differences on the 0±100 RAND scales of 6.5 points in the physical health dimensions and 7.9 points in the mental health dimensions are considered to be clinically meaningful. 38 Differences on the 0±100 UCLA scales of 10 points are considered by its authors clinically meaningful. Missing data elements were treated with pairwise deletions. Multivariate regression analysis was performed on baseline and change scores with the HRQOL domains serving as dependent variables and the sociodemographic and clinical variables as independent (predictor) variables. Categorical variables were analyzed as dummy variables as follows, with the reference category indicated in italics: marital status (unmarried vs married), insurance status (Health Maintenance Organization vs Medicare, Medicare with Supplemental, Preferred Provider Organization/Feefor-Service), education level completed (high school vs college graduate or higher, some college), race (non-white vs white), and tumor stage (T2C/T3/T4 vs T1, T2A/T2B). Age, income, and number of comorbidities were treated as continuous variables. Treatment was not included as a regression variable because it signi®cantly covaried with tumor stage and because we did not have suf®cient sample size in all treatments to analyze them individually. All data were analyzed using the SAS System for Windows, Version 6.12 (SAS Institute, Cary, NC).
Results
The mean patient age at baseline was 67.7 y (s.d. 7.5; median 67.4; range 47±86). About half the patients (49%) were between 60 and 70 y old. A demographic pro®le of the sample at enrollment into the study is presented in Table 1 . Almost 90% of the patients identi®ed themselves as Caucasian. Although a wide range was seen in income, three-fourths of patients had annual household incomes under $75 000. Over 90% of patients were married and co-habitating with a partner. Although 60% of patients had Medicare, various forms of insurance coverage were noted. Fully 75% of patients had one or more chronic medical conditions at the time of diagnosis. All clinical stages of prostate cancer were included in the study sample. Lastly, a variety of treatment choices is represented in our study sample: radical prostatectomy (48%), pelvic irradiation (10%), watchful waiting (12%), androgen ablation (24%), and androgen ablation with surgery or radiation (6%).
HRQOL scores in the general and disease-speci®c domains at baseline and at nine months are shown in Table 2 . During the nine months following diagnosis, several signi®cant increases were noted. Marked improvements were seen in the SF-36 domains of Role Limitations Due to Physical Problems ( 14.9, P 0.0006), Social Functioning ( 7.8, P 0.0004), and Health Change ( 14.6, P 0.0001). Signi®cant improvement was also noted in Urinary Function ( 13.2, P 0.0001), Urinary Bother ( 14.4, P 0.0001), Sexual Results from the multiple regression analysis of sociodemographic predictors of baseline general and diseasespeci®c HRQOL scores are shown in Tables 3 and 4 . Married men were found to have better HRQOL scores than unmarried men in Emotional Well-Being ( 11.8, P 0.017) and Family Functioning ( 16.9, P 0.01). Scores on the Cancer Interference with Family domain trended higher in married men (13.1, P 0.06). Married men also scored signi®cantly better than unmarried men in Bowel Function (15.5, P 0.019) and Bowel Bother (21.1, P 0.023).
Analysis of health insurance coverage as a predictor of baseline HRQOL revealed that patients who had Medicare with Supplemental Insurance scored signi®cantly worse in the SF-36 domains of Role Limitations Due to Emotional Problems (À19.6, P 0.04), Energy/Fatigue (À13.9, P 0.02), and Emotional Well-Being (À10.5 P 0.01). In addition, those who were enrolled in health maintenance organizations (HMOs) tended to score better in the Sexual Bother domain (P 0.06) than did men with any other type of coverage.
Patients with non-palpable tumors (T1) had better general HRQOL scores than did men with more locally advanced disease (T2C/T3/T4) in the domains of Role Limitations Due to Physical Problems (26.4, P 0.009) and Role Limitations Due to Emotional Problems (18.8, P 0.015). Patients with palpably limited (T2A/T2B) disease also had better baseline HRQOL scores in the domains of Role Limitations Due to Physical Problems (22.4, P 0.03), Role Limitations Due to Emotional Problems (18.8, P 0.013), and Social Functioning (12.2, P 0.04) than those with stage T2C or greater disease. Compared to men with the most locally advanced tumors (T2C/T3/T4), Urinary Function was better in men with T1 (17.2, P 0.012) or T2A/T2B disease (16.0, P 0.024). Conversely, men with T1 tumors had poorer Bowel Bother scores than did men with more advanced disease (À12.6, P 0.04).
Increasing age was associated with better baseline scores in Urinary Function (1.7 points per year, P 0.0006), Urinary Bother (1.26 points per year, P 0.036), and Bowel Function (0.8 points per year, P 0.012). No correlation was seen between age and Sexual Function or Sexual Bother. Increasing comorbidity counts were associated with poorer general HRQOL but no difference in the sexual, urinary, or bowel domains.
Results from the multivariate analysis of sociodemographic and clinical predictors of the 9-month changes in general and disease-speci®c HRQOL scores are shown in Tables 5 and 6 . Married men experienced signi®cant worsening in their Family Functioning when compared to unmarried men (À18.5, P 0.006) during the 9-month interval. However, marital status did not correlate with changes in any other HRQOL domain. Those with some college education noted worsening in Bowel Function (À11.0, P 0.03) compared to men without any college education, although college graduates reported similar Bowel Function changes to those without a college education. Patients with earlier stage (T1) tumors reported signi®cantly more negative 9-month changes in Physical Functioning (À10.1, P 0.048) and Role Limitations Due to Physical Problems (À21.8, P 0.05) but greater gains in Bowel Function (11.8, P 0.006) when compared to men with larger tumors. Men with T2A/T2B disease reported greater 9-month drops in Sexual Function (À8.6, P 0.04) and Sexual Bother (À24.0, P 0.008) than men with more locally advanced tumors.
Increasing age had an adverse effect on 9-month changes in general and disease-speci®c HRQOL domains, including Emotional Well-Being (À0.5 points per year, P 0.014), Social Functioning (À0.9 points per year, P 0.03), Health Change (À1.1 points per year, P 0.02), Urinary Function (À1.1 points per year, P 0.003), and a trend toward worse Urinary Bother levels (À1.5 points per year, P 0.055). Older patients had paradoxical ®ndings in the bowel domains with decreased Bowel Function (À0.9 points per year, P 0.002) but improved Bowel Bother (1.1 points per year, P 0.02). Higher comorbidity counts were associated with improved 9-month performance on the Sexual Bother scale (7.3, P 0.01).
Discussion
The data presented in this study indicate that during the nine months following the initial diagnosis of prostate cancer, improvement is seen in many areas of quality of life. In particular, three general domains, Role Limitations Due to Physical Problems, Social Functioning, and Health Change, improve signi®cantly. We speculate that this happens because as time progresses, patients become more comfortable with their diagnosis and treatment choice, and their perceived quality of life improves Mean change scores were calculated by subtracting baseline scores from 9-month scores.
Mean change scores were compared to zero using the paired Student t-test. * P`0.05; ** P`0.001. ns non-signi®cant. In the case of each categorical predictor variable, a comparison was made to a reference category, indicated in parentheses for each category. Income, age and comorbidity count were treated as continuous dimensional variables, so the estimates of effect are expressed per unit change in the independent predictor variable.
accordingly. This is consistent with the ®ndings of Braslis and colleagues, 10 who used the Functional Living IndexÐ Cancer (FLIC) and the Pro®le of Mood States (POMS) to compare HRQOL scores in patients one year following radical prostatectomy with a separate group of prostate cancer patients awaiting the same operation. They demonstrated that despite a deterioration in sexual function and urinary continence following surgery, there was an improvement in Emotional Tension score. The ®nding that our patients experienced improved Urinary Function, Sexual Function and Urinary Bother nine months after diagnosis seems counterintuitive. It is important to remember, however, that our sample includes patients undergoing a variety of treatments for various stages of disease. Hence, the improvements in the disease-speci®c domains may not be unexpected as patients become accustomed to their new quality of life. Patients' families also appear to become more comfortable with the diagnosis and treatment of prostate cancer during the ®rst nine months as evidenced by improved Cancer Interference with Family scores.
Comorbidity count was inversely associated with baseline general HRQOL, a ®nding that is consistent with prior studies 24 and clinical experience, as sicker patients are expected to report poorer general quality of life. This adds credence to the performance of the SF-36 in our patient population. Interestingly, there appears to be no association between increasing comorbidity and diseasespeci®c domains of HRQOL at baseline. This observation is consistent with prior work in men with prostate cancer 3 and in other patient population 25 , 26 and underscores the importance of using both general and disease-speci®c instruments to capture a full pro®le of patients' experience with illness. 27 The number of comorbidities appears to have no association with a change in general HRQOL scores at nine months, but it does correlate with improved Sexual Bother scores, suggesting that sicker patients are less concerned about sexual dysfunction. Surprisingly, there were no signi®cant differences between married and unmarried men in either the sexual or urinary domains, however married men did perform better in the bowel domains. The reasons for this are unclear. Several previous reports have examined the effect of marital status on outcomes in prostate cancer and other malignancies. Krongrad et al 17 used data from the Surveillance, Epidemiology and End Results (SEER) database to show that, after controlling for age, race, tumor stage, and treatment, married patients have a lower risk of mortality from prostate cancer. Although survival may be enhanced in married patients, improved quality of life does not necessarily follow. Marital status has been shown to have little effect on quality of life in cancer in general, 28 although it does appear to have a positive effect on general and disease-speci®c HRQOL in patients with head and neck cancer. 26 Perhaps the involvement of intimate organs in prostate cancer sets it apart from other cancers. Indeed, patients with a disease that causes urinary or sexual dysfunction may have added stress due to the presence of a spouse or signi®cant other. 17 That married status correlates negatively with 9-month change in Family Functioning, despite better baseline Emotional Well-Being and Family Functioning, supports this explanation. Married patients may havè more to lose' and, therefore, be more profoundly affected in these domains.
Our data show that HMO patients reported markedly better Sexual Bother scores (less bother) than did those with Medicare, preferred provider organization (PPO), or fee-for-service coverage. This may be because HMOs coordinate bene®ts more comprehensively and hence patients feel less bothered by a dysfunction that might otherwise cause embarrassment and frustration. Another surprising trend revealed that patients who are covered by Medicare and supplemental insurance performed signi®cantly worse than HMO patients in Energy/Fatigue and in both emotional domains of the SF-36. This ®nding ns non-signi®cant.
Quality of life predictors in prostate cancer DF Penson et al is curious because the effect sizes are so striking. Prior studies examining the effect of managed care on patientreported health outcome measures are equivocal. Perneger et al 29 prospectively examined SF-36 scores in a population of healthy, young patients who switched from indemnity health insurance to a managed care organization in Switzerland. They showed that insurance status had no effect on HRQOL in this patient population. Other studies have shown that in older, sicker patients with joint pain, HMO enrollees are less likely to report symptomatic relief than non-HMO enrollees. 30 Our ®nding that HMO patients report better general HRQOL scores than those with Medicare with supplemental insurance contradicts the previous study. Ultimately, further research in this area is needed to provide better explanations of the role of insurance status on HRQOL outcomes in prostate cancer.
Increasing education level has a paradoxical effect on Bowel Function and Bowel Bother. Compared to men with a high school degree or less, those with some college education perform worse in the bowel domains nine months after treatment. However, those with a college degree or higher do not perform worse than the least educated patients. One possible explanation of these ®ndings is that education level may be in¯uencing treatment choice, which in turn impacts the level of dysfunction. Prior research has shown that patients with prostate cancer undergoing radiation therapy are more likely to have gastrointestinal complaints than aged-matched controls or patients undergoing radical prostatectomy.
2,3,31±33
This effect is most pronounced at three months following therapy, and patients often return to baseline by one year after treatment. 8 In a neural network analysis, Krongrad et al 34 found that men with prostate cancer were more likely to enjoy better HRQOL if their education level was higher than the population mean. Conversely, Mazur et al 35 reported that education level was not related to treatment choice in older patients with prostate cancer. Interestingly, in breast and other malignancies, the opposite effect was found. 36, 37 Nonetheless, for unclear reasons, moderately educated men in this sample appear to have the greatest problems with their bowels.
Advancing age appears to have a slightly positive effect on baseline general HRQOL domains in our sample. This is incosistent with prior work with the SF-36, which has shown that increased age is associated with worsening general HRQOL scores in the general population. 38 The relative good health of our sample (nearly three-fourths have two or fewer comorbidities) may have diminished the expected age-related decline in baseline HRQOL. The clustering of patients in the older age range may also have attenuated the impact of age on baseline HRQOL scores. Alternatively, older patients in our sample may simply have a more positive outlook about their own general HRQOL, perhaps because of greater perceived access to health care.
The salutary effect of age on baseline HRQOL in this sample does not persist over time. During the nine months following diagnosis, older patients in our study experienced a slightly greater decrease in HRQOL scores than did younger patients in the general domains of Emotional Well-Being, Social Functioning and Health Change. This could indicate that a diagnosis of prostate cancer is harder on older men despite favorable ®nancial access to care. Although older patients are more likely to have clinically insigni®cant prostate cancer, 39 a diagnosis of prostate cancer may impose greater psychological stress on them. Indeed, Caffo et al 11 suggested that older patients had a harder time adjusting psychologically to their diagnosis, although this observation did not reach statistical signi®-cance. Furthermore, Krongrad's neural network model, 34 in which age was not a statistically signi®cant predictor of HRQOL outcomes in prostate cancer.
Tumor stage was found to be an important predictor of quality of life in this patient population at baseline. Men with lower stage disease have better general HRQOL at baseline, a ®nding that re¯ects clinical experience that those with earlier tumors are least likely to have systemic manifestations of their disease. This is consistent with previous studies. Ganz et al. 40 showed that HRQOL declines correlated directly with tumor stage in prostate and other cancers. In addition, van Andel et al 41 showed that PSA, which may act as a proxy for tumor stage in many cases, has an inverse relationship with HRQOL scores in patients with node-positive prostate cancer. Because tumor stage signi®cantly covaried with treatment choice, we did not include the latter in our regression. Treatment choice will be the subject of a future research effort, in which larger numbers of patients in each treatment group will allow for a more robust analysis of this important variable.
Tumor stage also predicts quality of life outcomes nine months after baseline. Patients with low stage disease (T1) reported decreases in the SF-36 Physical Function and Role-Physical domains. Because this is the group most likely to undergo radical prostatectomy, these changes may represent the lingering effects of surgery. Others have demonstrated prospectively that the physical domains of HRQOL do return to baseline with longer follow-up. 14 The presence of stage T1 disease was also predictive of better Bowel Function compared to more locally advanced stage T2C/T3/T4 disease, probably re¯ecting the greater likelihood more locally advanced patients receive radiation as primary therapy. This is consistent with other reports that patients undergoing radiotherapy for prostate cancer have a higher incidence of bowel dysfunction than do those treated with radical prostatectomy. 3, 16, 42 While T1 stage demonstrates no predictive value for Sexual Function or Sexual Bother nine months after baseline, T2A or T2B stage is associated with worsening of Sexual Bother scores when compared to T2C or greater stage. This ®nding may simply re¯ect differences in primary treatment choice.
Our study has several important limitations. Firstly, although prospective, the data are not randomized. CaPSURE TM represents a heterogeneous population of prostate cancer patients in a variety of clinical practice settings. This type of research design, while representing the full spectrum of prostate cancer patients, may introduce selection bias into the results. Because of this potential for bias, it is dif®cult to draw de®nitive conclusions regarding the relationship of treatment choice and HRQOL outcomes. Secondly, our sample has little ethnic diversity. This may be another source of selection bias and prevents us from making any comments on the relationship of race and quality of life outcomes. Thirdly, studies such as ours may suffer from the problem of multiple comparisons, even though we de®ned a number of a priori hypotheses. Fourth, tumor stage may be acting as a proxy for treatment choice, a variable we did not control for in the present analysis. While treatment choice certainly affects HRQOL, we were more interested here in describing the effects of sociodemographic variables. Including treatment choice in the regression would likely have led to spurious regression results from double counting of this variable. Finally, the explanations we provide for observed outcome differences must be considered speculative, though each provides an opportunity for future hypothesis-driven research.
Although observational database methodology does not contain the rigorous control mechanisms that are found in randomized clinical trials, the heterogeneity of the CaPSURE TM population does yield new insight into patients' experience with prostate cancer across the health care system today. Observations regarding the effect of marital status, comorbidity, age, education level, and tumor stage on HRQOL can provide practitioners with important information to communicate to patients on what to expect during their disease course. Furthermore, our demonstrated ®ndings on the effect of insurance status on HRQOL may inform future policy debates regarding prostate cancer.
Conclusion
We examined the effect of prostate cancer upon HRQOL immediately following diagnosis and over a 9-month interval in a heterogeneous population of patients. No attempt was made to control for treatment choice, as the population was meant to represent the wide spectrum of disease and treatment options available to patients today. Over the 9-month interval from diagnosis, patients had signi®cant improvements in their general HRQOL in both physical and emotional domains. In addition, improvements were noted in the Sexual Function and Bother, Urinary Bother and Bowel Function and Bother domains, when compared to baseline. Clinical and sociodemographic predictors of baseline HRQOL and change in HRQOL were identi®ed. Married patients were found to have better scores in emotional domains at baseline, but later declined over nine month study period. In addition, insurance status was found to be a predictor of Sexual Bother at baseline, with patients in HMOs having signi®cantly higher scores than other types of insurance. Patients with lower stage disease were noted to have better general HRQOL at baseline, although decreases in the physical domains were noted at nine months. Patients with early stage palpable tumors (T2A or T2B) were found to have worse outcomes in the sexual domains nine months following diagnosis. These data shed new light on patients' experience with prostate cancer and suggest that change in HRQOL outcomes over time may occur in a predictable manner.
